Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® Plus LENVIMA® Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, … Applications Based on Progression-Free Survival, Overall Survival, and Objecti...
Source: investingnews.com